Brokerages expect Teleflex Incorporated (NYSE:TFX) to report $2.40 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Teleflex’s earnings. The lowest EPS estimate is $2.37 and the highest is $2.46. Teleflex posted earnings of $2.13 per share during the same quarter last year, which indicates a positive year over year growth rate of 12.7%. The firm is scheduled to report its next earnings report on Thursday, February 22nd.

On average, analysts expect that Teleflex will report full-year earnings of $8.36 per share for the current fiscal year, with EPS estimates ranging from $8.33 to $8.42. For the next year, analysts anticipate that the company will report earnings of $9.68 per share, with EPS estimates ranging from $9.60 to $9.85. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Teleflex.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.01 by $0.11. The company had revenue of $534.70 million for the quarter, compared to the consensus estimate of $522.94 million. Teleflex had a net margin of 12.41% and a return on equity of 16.27%. The firm’s revenue was up 17.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.80 EPS.

TFX has been the topic of several analyst reports. Leerink Swann reiterated a “buy” rating and set a $321.00 price target (up from $307.00) on shares of Teleflex in a report on Tuesday, January 30th. Stephens reiterated a “buy” rating and set a $300.00 price target on shares of Teleflex in a report on Thursday, January 18th. Jefferies Group upped their target price on shares of Teleflex from $270.00 to $295.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Needham & Company LLC upped their target price on shares of Teleflex from $237.00 to $285.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Finally, Morgan Stanley upped their target price on shares of Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $283.89.

In other news, Director George Babich, Jr. sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $283.11, for a total value of $707,775.00. Following the completion of the sale, the director now owns 9,581 shares of the company’s stock, valued at approximately $2,712,476.91. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $248.96, for a total transaction of $49,792.00. Following the completion of the sale, the director now directly owns 8,080 shares of the company’s stock, valued at approximately $2,011,596.80. The disclosure for this sale can be found here. Insiders sold a total of 7,600 shares of company stock worth $2,040,569 over the last 90 days. Insiders own 2.39% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in TFX. Toronto Dominion Bank lifted its position in shares of Teleflex by 14.5% in the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 70 shares during the period. Advisory Services Network LLC lifted its position in shares of Teleflex by 933.8% in the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after purchasing an additional 747 shares during the period. Cornerstone Capital Management Holdings LLC. purchased a new stake in Teleflex during the second quarter valued at approximately $175,000. Archford Capital Strategies LLC lifted its position in Teleflex by 29,025.0% during the second quarter. Archford Capital Strategies LLC now owns 1,165 shares of the medical technology company’s stock valued at $217,000 after acquiring an additional 1,161 shares during the last quarter. Finally, Coldstream Capital Management Inc. purchased a new stake in Teleflex during the third quarter valued at approximately $226,000. 88.86% of the stock is owned by hedge funds and other institutional investors.

Shares of Teleflex (NYSE TFX) traded down $0.25 during trading hours on Friday, reaching $272.11. 59,113 shares of the company traded hands, compared to its average volume of 277,670. The company has a market cap of $12,269.62, a P/E ratio of 33.67, a price-to-earnings-growth ratio of 2.01 and a beta of 1.15. Teleflex has a one year low of $169.15 and a one year high of $288.78. The company has a debt-to-equity ratio of 0.88, a current ratio of 4.72 and a quick ratio of 3.70.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was stolen and reposted in violation of United States & international copyright and trademark laws. The correct version of this piece of content can be read at https://www.watchlistnews.com/teleflex-incorporated-tfx-expected-to-announce-earnings-of-2-40-per-share/1846227.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.